These pleiotropic effects position SGLT2 inhibitors as promising multitarget therapeutic agents for addressing diabetes-related cognitive impairment; however, additional clinical validation is required to confirm their efficacy and safety. This evidence concerns the gene SLC5A2 and Cognitive impairment.